Severe pneumococcal pneumonia: New strategies for management

Current Opinion in Critical Care

Volumn 12, Issue 5, 2006, Pages 470-476

  Chiou, Christine C C ^a   Yu, Victor L ^b,c  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Penicillin; Pneumococcal pneumonia; Streptococcus pneumoniae

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; BETA LACTAM; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; IMMUNOGLOBULIN; MACROLIDE; PENICILLIN G; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; QUINOLONE;

ANTIGEN ANTIBODY REACTION; BACTEREMIA; BLOOD CULTURE; CELL WALL; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG EXPOSURE; HUMAN; IMMUNOASSAY; IMMUNOTHERAPY; INFECTION RISK; INFLAMMATION; INTENSIVE CARE UNIT; LOBAR PNEUMONIA; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NASOPHARYNX; PATHOGENESIS; PHAGOCYTE; REVIEW; STREPTOCOCCUS PNEUMONIAE; TISSUE INJURY; TREATMENT OUTCOME;

ADULT; BACTEREMIA; CHILD; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MACROLIDES; PENICILLINS; PNEUMONIA, PNEUMOCOCCAL;

EID: 33748416496     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/01.ccx.0000244129.69742.d9     Document Type: Review

References (71)

1. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999; 281:61-66.
2. Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31:383-421.
3. Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60:759-776.
4. Plouffe JF, Martin DR. Re-evaluation of the therapy of severe pneumonia caused by Streptococcus pneumoniae. Infect Dis Clin North Am 2004; 18:963-974.
5. Georges H, Leroy O, Vandenbussche C, et al. Epidemiological features and progress of severe community-acquired pneumococcal pneumonia. Intensive Care Med 1999; 25:198.
6. Ioachimescu OC, Ioachimescu AG, Iannini PB. Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience. Int J Antimicrob Agents 2004; 24:485-490.
7. Yu VL, Kellog JA, Plouff JF, et al. Evaluation of the Binax urinary gram stain and sputum culture for Streptococcus pneumoniae in patients with community-acquired pneumonia [abstract]. Clin Infect Dis 2000; 32:258.
8. Murdock DR, Laing RTR, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001; 39:3495-3498.
9. Smith MD, Derrington P, Evans P, et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urine antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol 2003; 41:2810-2813.
10. Ortqvist A, Hedlund J, Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med 2005; 26:563-574.
11. Chiou CC. Does penicillin remain the drug of choice for pneumococcal pneumonia in view of emerging in vitro resistance? Clin Infect Dis 2006; 42:234-237. The pharmacodynamics of penicillin and the historical context of how Clinical and Laboratory Standards Institute breakpoints were formulated demonstrates why penicillin is effective against penicillin-'resistant' pneumonia.
12. Deeks S, Palacio R, Ruvinsky R, et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. Pediatrics 1999; 103:409-413.
13. Straus WL, Qazi SA, Kundi Z, et al. Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxycillin for pneumonia among children in Pakistan: randomized controlled trial Pakistan Co-trimoxazole Study Group. Lancet 1998; 352:270-274.
14. Aspa J, Rajas O, Rodriguez de Castro F, et al. Pneumococcal Pneumonia in Spain Study Group Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 2004; 38:787-798.
15. Aspa J, Rajas O, Castro FR. Reply to Yu and Baddour. Clin Infect Dis 2004; 39:1087-1088.
16. Carratalà J, Marron A, Fernàndez-Sevilla A, et al. Treatment of penicillin-resistant pneumococcal bacteremia in neutropenic patients with cancer. Clin Infect Dis 1997; 24:148-152.
17. Castillo EM, Rickman LS, Brodine SK, et al. Streptococcus pneumoniae: bacteremia in an era of penicillin resistance. Am J Infect Control 2000; 28:239-243.
18. Ewig S, Ruiz M, Torres A, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999; 159:1835-1842.
19. Falcó V, Almirante B, Jordano Q, et al. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediate resistant strains? J Antimicrob Chemother 2004; 54:481-488.
20. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance. Am J Public Health 2000; 90:223-229.
21. Friedland IR, Klugman KP. Antibiotic-resistant pneumococcal disease in South African children. Am J Dis Child 1992; 146:920-923.
22. Friedland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis 1995; 14:885-890.
23. File TM Jr, Jacobs MR, Poole MD, Wynne B. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains with pharmacokinetically enhanced amoxycillin/ clavulanate. Int J Antimicrob Agents 2002; 20:235-247.
24. File TM, Lode H, Kurz H, et al. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin (2000/125 milligrams) vs those of amoxicillin-clavulanate (875/125 milligrams) both given twice daily for 7 days in treatment of bacterial community-acquired pneumonia in adults. Antimicrob Agents Chemother 2004; 48:3323-3331.
25. Gonzalez BE, Martinez-Aguilar G, Mason EOJR, Kaplan SL. Azithromycin compared with beta-lactam antibiotic treatment failures in pneumococcal infections of children. Pediatr Infect Dis J 2004; 23:339-405.
26. Kalin M, Ortqvist A, Almela M, et al. Prospective study of prognostic factors in community-acquired bacteremia pneumococcal disease in 5 countries. J Infect Dis 2000; 181:840-847.
27. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474-480.
28. Pallares R, Capdevila O, Linares J, et al. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am J Med 2002; 113:120-126.
29. Peterson LR. Penicillins for therapy of pneumococcal pneumonia: does in vitro resistance really matter? Clin Infect Dis 2006; 42:224-233. In this review of over 7000 patients, only a single report of documented microbiologic failure of parenteral penicillin-class antibiotics in the treatment of pneumococcal pneumonia was found, whereas 21 reports of treatment failure with quinolone-class and 35 reports of macrolide-class antibiotics for the treatment of pneumococcal pneumonia were found.
30. Plouffe JF, Breiman RF, Facklam RR. Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group. JAMA 1996; 275:194-198.
31. Rosón B, Carratala J, Tubau F, et al. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone. Microb Drug Resist 2001; 7:85-96.
32. Rosón B, Carratalà J, Fernandez-Sabé N, Tubau F, et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004; 164:502-508.
33. Turett GS, Blum S, Fazal BA, et al. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999; 29:321-327.
34. Song JH, Jung SI, Ki HK, et al. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 2004; 38:1570-1578.
35. Yu VL, Klugman KP, Ortqvist A, et al. Reply to questions on peumococcal bacteremia (Yu VL et al.) Clin Infect Dis 2003; 37:230-237.
36. Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J. Breakthrough pneumococcal bacteremia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother 2003; 51:691-696.
37. Watanabe H, Sato S, Kawakami K, et al. A comparative clinical study of pneumonia by penicillin-resistant and -sensitive Streptococcus pneumoniae in a community hospital. Respirology 2000; 5:59-64.
38. Musher DM, Bartlett JG, Doern GV. A fresh look at the definition of susceptibility of Streptococcus pneumoniae to b-lactam antibiotics. Arch Intern Med 2001; 161:2538-2544.
39. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial testing. 12th informational supplement. NCCLS document M100-S12. Wayne: NCCLS 2002.
40. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22:89-96.
41. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-12.
42. Andes D. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2001; 14:165-172.
43. Bryan CS, Talwani R, Stinson MS. Penicillin dosing for pneumococcal pneumonia. Chest 1997; 112:1657-1664.
44. Bishai W. The in-vivo and in-vitro paradox in pneumococcal respiratory tract infections. J Antimicrob Chemother 2002; 49:433-436.
45. Rieux V, Carbon C, Azoulay-Dupuis E. Complex relationship between acquisition of beta-lactam resistance and loss of virulence in Streptococcus pneumoniae. J Infect Dis 2001; 184:66-72.
46. Azoulay-Dupuis E, Rieux V, Muffat-Joly M, et al. Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice. Antimicrob Agents Chemother 2000; 44:1575-1577.
47. Trzcinski K, Thompson CM, Gilbey AM, et al. Incremental increase in fitness cost with increased beta-lactam resistance in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. J Infect Dis 2006; 193:1296-1303. Colonization of the upper respiratory tract precedes pneumonia. Virulent pneumococci were transformed into variants resistant to penicillin. These variant pneumococci showed decreased virulence in rats. When penicillin-binding protein alleles were acquired in pneumococci, these resistant pneumococci were less likely to colonize the nasopharnyx of rats as compared to susceptible pneumococci.
48. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405-1433.
49. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy may lower mortality for severe Streptococcus pneumoniae bacteremia: an international prospective multicenter study. Am J Resp Crit Care Med 2004; 170:440-444.
50. Garcia Vazquez E, Mensa J, Martinez JA, et al. Lower mortality among patients with community-acquired pneumonia treated with macrolide plus a betalactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Dis 2005; 24:190-195.
51. Gleason P, Meehan TP, Fine JM. Association between antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159:2562-2572.
52. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study. Am J Med 1999; 104:34S-43S.
53. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a betalactam-based empirical antibiotic regimen associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:389-395.
54. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1873-1842.
55. Weiss K, Low DE, Cortes L, et al. Clinical characteristic at initial presentation an impact of dual therapy on the outcome of Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004; 11:589-593.
56. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 371:230-237.
57. Guchev IA, Yu VL, Sinopalnikov A, et al. Management of non-severe pneumonia in military trainees using the urinary antigen test for Streptococcus pneumoniae: an innovative approach to targeted therapy. Clin Infect Dis 2005; 40:1608-1616. This study of 219 immunocompetent young males demonstrated a practical application of a rapid diagnostic method. Penicillin was given as targeted therapy for CAP patients with a positive urinary antigen test for pneumococci, while clarithromycin was given if the urinary antigen test was negative. Efficacy in both groups was similar (over 90%). Patients with positive urinary antigen tests also had more prolonged time for resolution of symptoms underscoring the point that pneumococcal pneumonia is more severe than pneumonia due to other respiratory pathogens
58. Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998; 351:399-403.
59. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270:1826-1831.
60. Jackson LA, Neuzil KM, Yu O, et al. Vaccine safety datalink effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747-1755.
61. Sims RV, Steinmann WC, McConville JH, et al. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1998; 108:653-657.
62. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people [Erratum in: JAMA 2000; 19:283-341]. JAMA 1997; 278:1333-1339.
63. Whitney CG, Farley MM, Hadler J, et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-1746.
64. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl JMed 2001; 345:1368-1377.
65. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367.
66. Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein Cfor severe sepsis. N Engl J Med 2001; 344:699-709.
67. Laterre PF, Garber G, Levy H, et al. PROWESS Clinical Evaluation Committee. Severe community-acquired pneumonia as a cause of sever sepsis: data from the PROWESS study. Crit Care Med 2005; 33:952-961.
68. De Hennezel L, Ramisse F, Binder P, et al. Effective combination therapy for invasive pneumococcal pneumonia with ampicillin and intravenous immunoglobulins in a mouse model. Antimicrob Agents Chemother 2001; 45:316-318.
69. Kaplan SL, Mason EO Jr, Wald E, et al. Six year multicenter surveillance of invasive pneumococcal infections in children. Pediatr Infect Dis 2002; 21:141-147.
70. Tan TQ, Manson EO Jr, Wald ER, et al. Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics 2002; 110:1-6.
71. Harbarth S, Garbino J, Pugin J, et al. Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis 2005; 24:688-690.